New York, USA, Oct. 30, 2023 (GLOBE NEWSWIRE) Idiopathic Pulmonary Fibrosis Market to Show Immense Growth at a CAGR of 6.6% During the Study Period (2019–2032) | DelveInsight The overall market of
The overall market of idiopathic pulmonary fibrosis is expected to rise due to increasing prevalent cases over the globe and thus the surge in treatment options. The expected launch of emerging therapy for idiopathic pulmonary fibrosis treatment, will boost the idiopathic pulmonary fibrosis market in the forecasted period (2023–2032).New York, USA, Oct. 30, 2023 (GLOBE NEWSWIRE) Idiopathic Pulmonary Fibrosis Market to Show Immense Growth at a CAGR of 6.6% During the Study Period (2019–2032) |
Esbriet, and Ofev (tyrosine kinase inhibitors). Both drugs have been shown to slow the disease progression but do not significantly impact mortality.
The surge in Idiopathic Pulmonary Fibrosis market size is due to an increase in the prevalence of IPF patients in the 7MM, along with promising assets such as
RG 6354, Pamrevlumab,
Of all the emerging therapies, the most anticipated product to launch is the
RG 6354 (Roche). It has received Breakthrough Therapy Designation from the FDA. Apart from this, other products such as
Pamrevlumab,
, Ziritaxestat, GB0139, and others have demonstrated early promising results.
The IPF market will experience a boost in market growth owing to the factors such as the market entry of novel therapies aided by the grant given by the special regulatory designations, an increase in the aging population, and an increase in the prevalence of fibrotic diseases in those population. However, the poor prognosis of IPF patients, lack of curative